Allarity Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Allarity Therapeutics, Inc. (ALLR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $1.01 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $186504.00, a 54344.18% increase year-over-year.
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $342.56.
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $1.01, a 100.00% decline from fiscal 2024.
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4725600.00, a 43.73% decline from fiscal 2023.
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $8397600.00, a 115035516.44% increase from fiscal 2022.
- Allarity Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $7.30, a 135.48% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.01 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.01 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $1.01 10-Q · filed 2025-08-15 | ||||
| 2024-12-31 | $4725600.00 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $2606960.00 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $186504.00 10-Q · filed 2024-08-05 | ||||
| 2024-03-31 | $186504.00 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $8397600.00 10-K · filed 2025-03-31 | $13996.00 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $13975.00 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $13702.00 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $342.56 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $7.30 10-K · filed 2023-03-13 | ||||
| 2022-09-30 | $7.30 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | $3.10 10-K · filed 2022-05-17 | ||||
| 2020-12-31 | $13.00 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |